project id: TCGA-UCEC; case submitter id: TCGA-AX-A3FZ; source center: 23; state: released; a260 a280 ratio: 1.8; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.7; rna integrity number: 9.3; age at index: 33; days to birth: -12331; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1977; age at diagnosis: 12331; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 6.0; figo stage: Stage IIIB; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 658; initial weight: 100.0; oct embedded: false; preservation method: Unknown; sample id: 3e114d9b-a96e-4b58-84a0-ad0ecf10b199; sample submitter id: TCGA-AX-A3FZ-01A; portion id: 88534bcc-15c1-4001-a57f-af8008ef358c; portion submitter id: TCGA-AX-A3FZ-01A-11; slide id: 0be8c3aa-52df-40c0-8024-eb0d7dc6ce5a; slide submitter id: TCGA-AX-A3FZ-01A-01-TS1; percent lymphocyte infiltration: 1.0; percent monocyte infiltration: 0.0; percent necrosis: 3.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 3.0; percent tumor cells: 94.0; percent tumor nuclei: 96.0; section location: TOP;